BIBP 3226 Trifluoroacetate: Decoding the NPY/NPFF Axis in Cardiac Arrhythmia and Beyond

Introduction: Re-envisioning the NPY/NPFF System with Modern Antagonists

The neuropeptide Y (NPY) and neuropeptide FF (NPFF) systems have emerged as pivotal regulators of neural and cardiovascular function, playing critical roles in anxiety, pain modulation, and cardiac physiology. With the rise of precision molecular tools, researchers can now interrogate these pathways with unparalleled specificity. BIBP 3226 trifluoroacetate (SKU: B7155), a non-peptide NPY Y1 and NPFF receptor antagonist supplied by APExBIO, exemplifies this new standard. Its robust selectivity and well-characterized pharmacology enable advanced studies of the NPY/NPFF axis, particularly in deciphering complex signaling events like cAMP inhibition and the adipose-neural interface in cardiovascular regulation.

The NPY/NPFF Axis: An Expanding Frontier in Biomedical Research

NPY, one of the most abundant neuropeptides in the central and peripheral nervous systems, acts through multiple G protein-coupled receptors, including the Y1 subtype (NPY Y1 receptor). NPFF, another structurally distinct neuropeptide, modulates pain and cardiovascular responses through its own receptor family, notably NPFF2. Together, these systems orchestrate physiological responses to stress, pain, and metabolic challenges.

Recent research, including a groundbreaking study published in Cell Reports Medicine (Fan et al., 2024), has illuminated the role of the NPY Y1 receptor in mediating arrhythmic risk via the adipose-neural axis. This study demonstrated that adipocyte-derived leptin can increase NPY release from sympathetic neurons, activating Y1R on cardiomyocytes and promoting arrhythmogenic signaling through downstream effectors such as NCX and CaMKII. Importantly, selective inhibition of Y1R—precisely the mechanism targeted by BIBP 3226 trifluoroacetate—can attenuate this pathological cascade.

Mechanism of Action of BIBP 3226 Trifluoroacetate

Pharmacological Profile and Selectivity

BIBP 3226 trifluoroacetate stands out as a non-peptide antagonist with high affinity for both the NPY Y1 and NPFF receptors (Ki = 1.1 nM for rat NPY Y1, 79 nM for human NPFF2, and 108 nM for rat NPFF). Its structure (C29H32F3N5O5; MW 587.59) confers selectivity and stability, making it ideal for in vitro and in vivo studies. The compound appears as an off-white solid, with excellent solubility in DMSO (≥78 mg/mL), ethanol (≥73.2 mg/mL), and water (≥12.13 mg/mL with ultrasonic assistance).

Targeting cAMP Signaling and Beyond

BIBP 3226 trifluoroacetate is particularly valuable in mechanistic studies of cAMP signaling inhibition. By competitively antagonizing NPY Y1 and NPFF receptors, it blocks NPFF-induced inhibition of forskolin-stimulated cyclic AMP (cAMP) production. This property allows researchers to dissect the specific contributions of NPY and NPFF signaling to downstream second messenger pathways, which are critical in regulating neuronal excitability, synaptic plasticity, and cardiac myocyte function.

Physiological and Behavioral Impacts

Beyond cellular signaling, BIBP 3226 trifluoroacetate has been shown to block NPFF-dependent hypothermic and anti-opioid effects in rodent models. This positions the compound as a versatile research tool for investigating the NPY/NPFF system’s roles in anxiety, analgesia, and cardiovascular regulation—domains where fine-tuned receptor antagonism yields insights into both normal physiology and disease states.

Comparative Analysis: BIBP 3226 Trifluoroacetate Versus Alternative Approaches

While several peptide and non-peptide antagonists have been developed for NPY and NPFF receptors, BIBP 3226 trifluoroacetate offers a unique blend of selectivity, solubility, and ease of use. Peptide antagonists often suffer from rapid degradation, poor membrane permeability, and complex handling procedures, limiting their utility in certain experimental contexts. In contrast, the non-peptide nature of BIBP 3226 enables robust performance in both cell-based assays and animal models, facilitating studies that require sustained receptor blockade or detailed pharmacokinetic profiling.

For instance, earlier articles such as "Leveraging BIBP 3226 Trifluoroacetate to Decipher the NPY…" have outlined the transformative role of this compound in translational research, highlighting its application in anxiety and cardiovascular studies. However, this article delves deeper into the molecular underpinnings—specifically, the intersection of cAMP signaling and the adipose-neural axis in arrhythmogenesis—thereby providing a unique mechanistic perspective not previously explored in depth.

Advanced Applications in Cardiovascular Regulation Research

Dissecting the Adipose-Neural Axis in Cardiac Arrhythmia

The innovative work of Fan et al. (2024) has shifted the paradigm in cardiac arrhythmia research by implicating the adipose-neural axis as a driver of pathological electrical activity. In their stem cell-based coculture model, adipocyte-derived leptin was shown to activate sympathetic neurons, increasing NPY secretion and Y1R engagement on cardiomyocytes. This cascade enhanced the activity of Na⁺/Ca²⁺ exchanger (NCX) and calcium/calmodulin-dependent protein kinase II (CaMKII), culminating in arrhythmogenic phenotypes. Notably, pharmacological inhibition of Y1R significantly attenuated these effects, underscoring the value of selective antagonists such as BIBP 3226 trifluoroacetate for mechanistic studies and potential drug discovery (Fan et al., 2024).

Experimental Design Considerations

To maximize the utility of BIBP 3226 trifluoroacetate in cardiovascular regulation research, investigators should consider the following protocol recommendations:

• Solubility and Storage: Prepare stock solutions in DMSO or ethanol at recommended concentrations. Store the solid compound at -20°C; avoid long-term storage of solutions to maintain activity.
• Assay Selection: Utilize cAMP signaling assays, calcium imaging, and electrophysiological recordings to monitor NPY/NPFF pathway modulation.
• Controls: Include vehicle and peptide antagonist controls to confirm specificity and rule out off-target effects.

Translational Relevance

The capacity of BIBP 3226 trifluoroacetate to selectively block the neuropeptide Y receptor pathway and neuropeptide FF receptor pathway makes it indispensable for translational research. In particular, its use in coculture and organoid models aligns with emerging trends in precision cardiology and neurobiology, where understanding intercellular signaling is paramount. This article uniquely extends beyond prior works—such as the practical workflow focus in "BIBP 3226 trifluoroacetate: Reliable Antagonist for NPY/N..."—by emphasizing mechanistic dissection and experimental innovation in arrhythmia models.

Expanding Horizons: Anxiety Research and Analgesia Mechanism Study

NPY/NPFF System in Neurobehavioral Regulation

Beyond cardiovascular contexts, the NPY/NPFF axis is deeply involved in anxiety and pain modulation. BIBP 3226 trifluoroacetate’s high specificity for NPY Y1 and NPFF receptors allows for precise investigation of anxiety-like behaviors and analgesic mechanisms in preclinical models. By inhibiting receptor-mediated cAMP signaling and downstream neurotransmitter release, researchers can tease apart the relative contributions of these pathways to behavioral phenotypes.

Earlier content, such as "Targeting the NPY/NPFF Axis: Strategic Insights for Trans...", has discussed the strategic value of BIBP 3226 in translational settings. In contrast, this article provides a deeper mechanistic analysis and highlights advanced experimental designs—such as the use of real-time biosensors and multi-modal behavioral assays—that leverage the compound’s unique properties.

Innovative Models and Future Tools

The advent of stem cell-derived neural and cardiac tissues, combined with high-content imaging and optogenetics, opens new avenues for utilizing BIBP 3226 trifluoroacetate. For example, integrating this compound into multi-cellular systems enables researchers to map the dynamic interplay between NPY/NPFF signaling and physiological outcomes in a controlled environment. These approaches are poised to reveal novel therapeutic targets for anxiety disorders, chronic pain, and arrhythmias, moving beyond the descriptive to the predictive.

Ensuring Scientific Rigor: Quality Control and Research Use

APExBIO’s BIBP 3226 trifluoroacetate is supplied with rigorous quality control documentation, including purity (>98%), HPLC, MS, NMR data, and a Certificate of Analysis (COA). This ensures reproducibility and confidence in experimental outcomes. The product is intended strictly for scientific research use and should not be employed for diagnostic or medical purposes.

Conclusion and Future Outlook

As the field of NPY/NPFF system research advances, the demand for highly selective, reliable antagonists continues to grow. BIBP 3226 trifluoroacetate stands at the forefront of this movement, enabling researchers to dissect cAMP signaling inhibition, the neuropeptide Y and FF receptor pathways, and the intricate adipose-neural interactions that underlie complex pathologies such as cardiac arrhythmias and anxiety disorders. By building on the foundational insights provided by recent mechanistic studies (Fan et al., 2024) and addressing experimental needs unmet by peptide antagonists, this compound paves the way for innovative research and therapeutic discovery.

For detailed protocols, advanced applications, and additional context, researchers are encouraged to consult previous reviews such as "BIBP 3226 trifluoroacetate: Advancing NPY/NPFF Axis Resea...". However, the present article uniquely integrates recent discoveries on the adipose-neural axis and provides strategic guidance for leveraging BIBP 3226 trifluoroacetate in next-generation experimental models.

To explore specifications or purchase options, visit the APExBIO product page for BIBP 3226 trifluoroacetate.